Oncogene (1998) 17, 3531 ± 3538 ã 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc Keyword Index ± Volume 16

1,3-Butadiene 803 APL 2549, 2843 Brain tumour 321 2',3'-Dideoxycytidine 803 Apolipoprotein A-1 655 Brca1 61 3p21 153 Apoptosis 237, 335, 387, 443, 489, BRCA1 1031, 1097, 1161, 1713, 9p 2403 705, 779, 853, 933, 957, 1041, 2229, 3069 8-Hydroxyguanine 3219 1369, 1383, 1399, 1455, 1493, Brca2 61 10q 597 1533, 1587, 1593, 1713, 1789, BRCA2 2229, 2283 10q23 1743 1803, 1839, 1885, 1899, 1939, BRCA carriers 21 12-O-tetradecanoylphorbol 2103, 2177, 2243, 2695, 2885, BRCA2 481, 2767 acetate 3387 3029, 3069, 3105, 3123, 3133, Breakpoint 671 12p 2617 3269, 3323, 3461 Breakpoint cloning 3151 g-radiation 721 Apoptotic cell death 2905 Breast cancer 21, 265, 301, 327, g-radiations 1041 Arachidonic acid 417 817, 1031, 1391, 1649, 1713, g-ray irradiation 2747 Asbestos 1041 1839, 2087, 2103, 2159, 2229, Associated 1141 2459, 2647, 2803, 2815, 2865, a-actin 1299 Astrocytes 1955 3151, 3299 abl 1319 Ataxia telangiectasia 721 Breast carcinoma 2723 ABP140 121 ATF2 523 Breast neoblasts 2927 ACTH-tumour 69 ATM 789 Burkitt's lymphoma 1603 Actin cytoskeleton 2011 AUF1 alternative exon 3413 Actin 147 Autocrine 2565 Activation 113 Autoimmune thyroiditis 665 c-Abl tyrosine kinase 1643, 1779 Acute leukemias 2895 Autophosphorylation sites 2657 c-Abl 1773 Ad-PML 1839 Axl 3177 C-cells 167 Adapters 1903 c-erbB3 3243 Adenomedullin 409 c-ErbB-2/HER2/Neu 301 Adenoviral-mediated b catenin 2819 c-Jun 2001 transfer 933 B-boxes 2905 c-Kit 179 Adenovirus 265, 349, 2041 B-cell di€erentiation 1885 c- 387 Adriamycin 705, 2229 B-lymphocytes 1553, 2165 c-myc 2755 AFAP-110 2185 BAG-1 2681 c-myc 3413 Aging 3197 Bax 1587, 1713 c-myc 5' UTR 423 Akt 825, 2407 BAX 1803 c-Rel 3133 ALL-1 3233 Bax 2767 c-Src 3349 Allelic loss 3455 BCL-2 family 3105 c-Yes, c-Src 3253 Allelic loss (or LOH) analysis 2747 Bcl-2 853, 933, 1383, 1587 C3G 613, 1229 Alternative processing 3243 BCL-2 2681 C6 rat glioma cells 3423 Alternative splicing 833, 991, 1701, Bcl-x 1383 Ca2+ ion 293 3219 Bcl-X 1399 Calcium 2095

AML1 2895 Bcl-XL 1493 cAMP 1325, 1665 Amplicon 191 BCL3 2333 Cancer 197, 555, 681, 1209, 1723, Ampli®cation 2997 Bcr serine/threonine kinase 141 2115, 2381, 3097, 3397, 3403 Anchorage 2575 Bcr tyrosine residues 141 Cancer gene therapy 547 Anchorage independence 179 Bcr null mutant 2029 Cancer genetics 1021, 1973 Anchorage-independent growth BCR±ABL 237, 489, 2585 Cancer Genome Anatomy Project 3159 Bcr ± Abl 1383 1633 Androgen 1913 BCR ± ABL oncogene 335 Candidate gene(s) 2617 Androgen 2001 Bcr/abl 1533 Canine lymphoma 249 Angiogenesis 409 Benign ovarian tumors 1639 Canine p53 germ line mutation 249 Anisomycin 575 Betacellulin 1209 Carcinogenesis 997, 2949 Annexin II 625 bFGF 3285 Carcinoid 69 Anthraquinone 2855 Bladder cancer 909, 933, 3215 Cartilage 2687 Antibody 1993 Bmi-1 oncoprotein 2541 Casein kinase II 2965 Antiproliferative activity 2687 Bone metastasis 693 Caspase 3029 Antisense 1899 Bone resorption 693 Caspases 2885 Antisense oligonucleotide 797, Borderline 197 Caveolin 1391 3445 BPDE 1241 Cdc42Hs 2513 Antisense RNA 1487 BPV-4 2739 CDF 2957 AP-1 activation 2975 Brain fatty acid binding protein CDK 217, 705, 2865 AP-1 131, 661, 779, 1611, 1731, 1955 cdk 3337 2843, 3057 Brain-metastatic melanoma 3253 CDK activity 2017 APC 77 Brain tumors 3323 CDK-activating kinase 217 Keyword Index ± Volume 16

3532 CDK inhibitor 1333 fragility 2311 D52-like proteins 873 Cdk inhibitors 755 Chromosome transfer 257 Dab 2381 CDK-inhibitors 217 Chromosome translocation 1409 Dab2 1561 cdk2 755, 2575 Chromosome Xq 197 Damaged DNA 1077 Cdk6 603 Chronic myeloid leukaemia (CML) Daunomycin 1187 cDNA 951 1319 Dbl 2513, 3279 cDNA array hybridization 1921 Cisplatin 533, 933, 2243 Dbl-homology (DH) domain 2597 Cell adhesion 2575, 2819 CKI 2865 DBM 481 Cell adhesion molecule, 1141 CLD 681 Deletion 1639 Cell cycle 131, 217, 311, 369, 399, Clinical course 1671 Deletion mapping 1891, 3331 587, 755, 797, 1041, 1289, 1333, Clonality 2557 Deletions 83, 635 1369, 1391, 1455, 1513, 1543, Cloning 1571 DEN 203 1655, 1825, 1885, 2575, 2729, CML 237 Dense-core granules 167 2803, 3115, 3337 Co-carcinogens 2739 Deubiquitinating enzyme 1767 Cell cycle arrest 3123 Coiled-coil 2905 Development 471, 1571 Cell cycle arrests 1789 Coiled-coil domain 809, 873 DHFR 1931 Cell cycle inhibitor 69 Cold shock 1507 Dibenzo[a,l]pyrene 3203 Cell cycle models 1065 Collagenase 1 2827 Di€erential display 327, 2447 Cell cycle regulation 1701 Colon cancer 1125, 1443, 3345 Di€erential expression 2945 Cell death 2787 Colorectal cancer 2389 Di€erential PCR display 409 Cell lineage 167 Computer simulation of reaction Di€erentiation 399, 443, 925, 967, Cell proliferation 1417, 1913, 3105, networks 1065 3471 3317 Connective tissue growth factor DIRVISH 1891 Cell proliferation and 747 DNA 3461 di€erentiation 1633 Conserved domains 3105 DNA binding 453, 1077, 1779, Cell transformation 843, 2739, Cortactin 3227 3013, 3123 2975, 3105 Cowden 2403 DNA damage 459, 533, 1113, Cell-cycle 603 CpG dinucleotides 1161 1351, 2229, 3069 Cell-free system 2781 CPP32/Caspase-3 387 DNA looping 283 Cellular immortalization 1217 CREB 1161 DNA methylation 3003, 3197 Cellular localization 2609 Critical region 2617 DNA repair 1241, 1789, 3083, Cellular senescence 1113 Crk 1903, 2425 3203, 3219 Cellular transformation 1085, 2017 Crk autophosphorylation site 1229 DNA replication 721 Ceramide 237 CRKL 1903 DNA topoisomerase II 1351 Cervical cancer 2447 Cross linker 1141 DNA-PK 1553 Cervix 2557 CRS 3309 DNA-virus 1945 Checkpoint 1825 Cushing's disease 69 DOC 2 1561, 2381 Chemotherapeutic agents 1587 CUTL1 1963 Dominant negative 273, 1939 Chemotherapeutic drugs 3269 CXXC motifs 1085 Dominant negative cJun 2711 Chernobyl 671 Cyclin 1333, 1455 Down-regulation 2321 Chicken 1357 cyclin A 2957 DRA 681 Chicken embryo 1611 Cyclin A 1277, 1373, 2489 Drug sensitivity 1617 Chimeric PKC 53 Cyclin B 431 DSRCT 1021, 1973 Choriocarcinoma 113 Cyclin D1 1267, 1701, 1913, 2489, DU-145 3069 Chromatin 1171 2865, 3445 Dysplasia 2351 Chromosomal translocation 2949 Cyclin dependent kinase inhibitors Chromosome 1825 265 Chromosome 1 2997 Cyclin dependent kinases 4 and E-cadherin 9 Chromosome 3 3151 6 587 E1A 349, 1655 Chromosome 3p21.3, 1097 Cyclin E 755, 2575, 2865 E1B 55K 2041 Chromosome 6 555 Cyclin-dependent kinase 311, 399, 957, 1065, 1267, 1289, Chromosome 6q 83 3445 1513, 2695, 2957, 3115 Chromosome 6q27 1639 Cyclin-dependent kinase E2F-1 1655, 2489 Chromosome 8p 2983 inhibitors 797 E2F-4 1655 Chromosome 9 89 Cyclin-dependent kinases 721, E4orf6 349 Chromosome 10 541, 909 2141 E6 1759 Chromosome 10p 257 Cyclins 2141, 2729 E6-AP 1759 Chromosome 10q 3215 Cytochrome c 1055 E7 homodimerization 1085 Chromosome 10q23.3 and 10q25- Cytochrome P450 2945 E7-E1A243 chimeric protein 1085 26 3331 Cytokeratin K17 2935 Early response gene 2479 Chromosome 10q25 1009 Cytokine 2671 EcoRI restriction enzyme 713 Chromosome 11 2755 Cytokines 417 EF1a 2011 Chromosome 13 481 Cytoplasmic anchorage 3423 EGF 1223, 2095 2159, 3455 Cytoplasmic shuttling 1429 EGF receptor 797, 1493 Chromosome 17p13 21 Cytoskeleton 43, 1299, 2185 EGFR 1869 Chromosome arm 10q 2879 Cytotoxicity 1209 EGFR 191 Keyword Index ± Volume 16

3533 egr-1 2915 FGFR1 gene 945 Glioblastoma multiforme 3197 Embryonal carcinoma 95, 3003, FHIT 635, 1863 Glioma 257, 321, 1009, 2243, 2997, 3471 Fibroblast growth factor 2151, 3435 Emodin 2855 2647 771 EMSA 453 FISH 1891 Glutaredoxin 2945 Endometrial tumours 3013 FISH mapping 2459 Glycerophosphoinositols 2357 Endometrium 409 Flow cytometry 721 Grb2 1561 Endothelial cells 359, 693 FLRG 2949 Growth arrest 311 Enhanced translation 1603 Flt-1 2585 Growth associated protein (GAP)- Entry 1851 Fluctuation analysis 2389 43 2945 EP element 1779 Fluorescence in situ hybridization Growth control 2479 Eph 471 789, 945, 2311 Growth factor receptor 843 Ephrin 471 Focus formation 613 Growth factors 417 Epidermal growth factor 1249 Follistatin 2949 Growth inhibition 431, 1391, Epidermal growth factor receptor Fos family 1611 1543 2565, 3435 Fos 2843, 3057 Growth suppressor 1525, 3115 Epidermal growth factor receptor Fps/Fes 2321 Growth suppressor protein 105 homologues 3243 Fra-1 3057 Gsp 985 Epigenetic 113 FRA3B 635 GST pull-down assay 873 Epithelial-mesenchymal transition FRA7G 2311 Guanine nucleotide exchange 9 Fractional allelic loss 2213 factor 2597 Epitope mapping 1993 Friend 2989 Gut epithelial cells 3445 EpoR 489 FRTL-5 cells 985 Epstein ± Barr Virus 1869 Fugu rubripes 3233 ErbB 2803 Full length canine p53 1077 H-ras proto-oncogene 3013 ErbB/HER family 1249 Functional assay 1369 h-neu gene 1009 Erk 131, 1691 H-ras 1789 ERK 2597 H19 2395 ERK cascade 2425 G1 arrest 1839 Hamster 3379 ERKs cascade 661 G1 cyclin 3337 HBV enhancer 1779 ERM 2065, 3279 G1 phase 2141 Head and neck cancer 1671 Erythroleukemia 563 G1/S phase transition 1065 Hedgehog 1091 ES cell 3189 Gain-of-function 3105 Hematopoiesis 925, 945 EST 191 Ganglioglioma 2259 Heparin-binding protein 747 Estrogen 381 Gastric adenocarcinoma 2681 Hepatitis B virus 1277, 2051, 2367 2513, 2647, 3197 Gastric cancer 2767 Hepatocellular carcinoma 203, Etoposide 1533, 2885 GDNF 293, 597, 2295 1277, 2367 Ets 301, 2065 GDP/GTP exchange factor 147 Hepatocyte growth factor Ets family 3261 Gene anatomy 327 receptor 833 Ets 1357 979, 1345, 3189, Hepatocyte growth factor-like Evi-1 2287 3387 protein receptor 27 Evolutionary conservation 3233 Gene expression regulation 1879 Hepatoma protein 1475 EWS 1973 Gene inactivation 2895 HER-2/neu 2087 EWS/ATF1 1325, 1625 Gene mapping 1955 HER-2/neu 547, 2855 EWS/WT1 1021 Gene promoter 1345 Herbimycin A 1533 Exon ampli®cation 1891 Gene regulation 2033, 2395 Heregulin 2803 Exon ± Intron 597 Gene structure 3243 hEST2 1217 Exon-skipping 833 Gene targeting 3097, 3189 Heterodimer 1197 Experimental metastasis 2855 Gene therapy 265, 685 HGF 9 Expression 1, 2407, 2723 Gene transcription 1345 HIC-1 2159 Extracellular matrix 747 Gene transfection 1913 Histological subtypes 83 Extra-cellular signal-related kinase Genetic polymorphism 3219 Histone acetyl transferase 2283 3039 Genetic recombination 3435 Histone deacetylases 2549 Genetics 3397 HIV-1 1851 Genomic imprinting 113, 2797 HL-60 1383 F-actin 121 Genomic instability 2755 HL-60 di€erentiation 915 F-actin-binding protein 121 Genomic organization 817 HMG-I(Y) 3387 FACS 1701 Genomic sequence 3233 HMGIC 865 FAK 3019 Genomic structure 833, 951 hMSH3 2767 Farnesyltransferase 1467 Genotoxic stress 1643 hMSH6 2767 Fas (Apo-1/CD95) 3029 Geranylgeranyltransferase 1467 Hodgkin's lymphoma 2131 FASAY 2527 Germ cell tumor 95, 2345 hOGG1 gene 3219 FceRI 3357 GFRa-1 597 gene 3285 Fetal liver 3413 Gleaning eciency 3203 Homozygous deletion 497, 3151, FGF2 2151 Glial ®brillary acidic protein 1955 3215 FGF8 1487 Glioblastoma 191, 541, 2259 Hox 3403 Keyword Index ± Volume 16

3534 HPRT 1125 Intermediate ®laments 3423 Lung cancer 497, 2469, 3057, HPV 2557, 2711 Internal initiation 423 3151 HPV (human papillomavirus) 2447 Internal ribosome entry segment Lymphoma 945, 1803, 2965 HRX 3233 (IRES) 423 Lyn 3357 HSP90 2639 Intracrine loop 3285 Lysophospholipids 2357 hTERT 1217 Intratumoral heterogeneity 1259 HTLV 2165 Intron 3435 HTLV-1 643, 3309 Invasion 625, 1443, 3227 M6p/Igf2r 2797 hTR 979, 1345 Ionizing radiation 1643, 2787 Mad family 967 Human breast cancer 677 IRS-1 2425 mad 2629 Human chromosome 11 2557 Malignant glioma 1955 Human chromosome pairs 6, 8, 9, Malignant transformation 613, 985 13, 945 JAK 505 Mammaglobin 817 Human endogenous retroviral JAKs 1749 Mammary 737 sequence 2311 JNK 779 Mammary carcinoma 3097 Human keratinocytes 2711 JNK/SAPK 1731 Mammary development 2755 Human leukemia 2729 JNK1 417, 533, 1501 Mammary tumors 1963 Human lung and kidney jun 2435, 2945 Manoclonal antibodies 883 cancer 3083 jun family 1611 MAP kinase 779, 2647, 2671, 2787, Human papilloma virus 1921 Jun 655, 3057 2803 Human papillomavirus type 16 E7 Jun kinase 131 MAP kinases 147, 575, 2915 protein 1085 Jun N-terminal kinase 3039 MAP4 1617 Human tumor cells 2885 Jurkat T cells 891 MAPK 1417, 2819, 3349 HUMORF8 1767 Mast cell 3357 Hypomyelination 2123 Matrix metalloproteinase 771 K562 1587 Max 967 KAI1 (CD82) 3143 2629 IkBa 2131 KAI1 gene 1443 MCF-7 131, 2229 ICAM-1 2065 Keratinocyte 853 MCF-7 growth inhibition 2647 IGF-1 1981 Keratinocytes 1493, 1501 MCK 283 IGF2 203 Ki-67 antigen 1701 MDM2 1603 IGFIIR 2767 Kidney 991 Mdm2 1183 IL-1 575, 1223 Kinase 471 mdm2 1171, 3317 IL-1R family 575 Kinase activity 2865 mdm2-P2 transcripts 2249 IL-2 1309 Kinase role of Bcr tyrosines 328 Meiosis 61, 1773, 1813 IL-2R 1309 and 360 141 Melanoma 523, 1681, 3047, 3397 IL-2R on carcinomas 1309 KruÈppel-like proteins 2549 Melanomas 2503 IL-3 1399, 1749 Ku autoantigen 1553 Membrane 2185 IL-15R 2503 MEN2B 2295 IL-15 2503 MEN2 2435 Immortalization 2103 lacZ tagging 2419 Mesothelioma 713, 3087 Immunohistochemistry 167, 327, Large E1B 349 MET receptor tyrosine kinase 833 1183, 2459 Lbc 2513 Metallothionein 2827 Imprinting 203 Lck 2351 Metallothionein-I promoter In situ hybridization 979, 1571 Leiomyoma/leiomyosarcoma 713 activation 1475 In-situ-hybridization, 1357 Leiomyomas 1963 Metastasis 9, 301, 1443, 3097 In vitro translation 873 Lens 399 Metastasis inhibition 2419 In vivo mutation 3203 Leucine-rich repeat 2997 Metastasis suppressor gene 3143 Incomplete penetrance 3211 Leukaemia 1533, 1803 Methylation 497, 1161, 2159, Indian hedgehog 1611 Leukaemogenesis 2287 2723 Inducible promoter 1879 Leukemia 925, 945, 1223, 2989 MHC class I 3299 INF 1945 Leukemia cells 779 mhox 227 Inhibition of Bcr serine kinase by Leukemia inhibitory factor 2671 Microphthalmia 1665 Bcr ± Abl 141 LIFR 1409 Microsatellite 909, 2983 Inositol 1:2-cyclic phosphate 2357 LIF 3189 Microsatellite instability 1803, Insertional mutation 3003 Li-Fraumeni 3291 2389, 2767, 3455 Instability 1825 Lipid metabolism 2357 Microtubule polymerization 1617 Insulin 2407 Liver cancer 2797 Middle-T 903 Insulin-like growth factor-II 2367 Liver protein 1475 Middle T antigen 2975 Integrin 43, 2773 Liver regeneration 2141 Migration 359 Integrin signaling 3159 LMP1 1731, 1869 MIP-1a 1319 Interferon 1543 LOH 21, 909, 2459, 2879 Mismatch repair 2389 Interferon a 1885, 2075 Loss of heterozygosity 197, 257, Mismatch repair gene 1259 Interferon-inducible genes 1543 555, 1743, 2213, 2983 Missense mutation 3211 Interferons 217 Loss of heterozygosity (LOH) 83 Missense mutations of OGG1 Interleukin-11 693 LPA 3019 gene 3083 Keyword Index ± Volume 16

3535 Mitochondrial transmembrane Neuroretina 2351 p21Waf1/Cip1 3461 potential 1055, 2265 Neurotrophin-3 3253 p21Cip-1 2787 Mitosis 61, 1813 Neurotrophins 3253 p21Cip1 2075 Mitotic arrest 2151 Neurturin 293 p21CIP1/WAF1 311 MLL 1351 NF-kB 1187, 1731, 1869, 2033, p21WAF1 443, 1885, 2213 MLL 3233 2051, 2095, 2131, 2333, 3133, p21WAF71 3317 MMAC1 2403 3299 p21WAF1/CIP1 1713 MMSP 1625 NFIB 865 p21Cip1 2575 mnt 2629 NGF 443 p27 1455, 2017 Molecular chaperones 2639 NIH3T3 53, 2819 p27Kip1 755, 3337 Molecular cloning 2459 NIH3T3 ®broblasts 1525 p27-kip1 69 Molecular oncology 327 NIMA 1813 p27Kip1 2575 Molecular reaction diagrams 1065 NLS 2151 p36/38 891 Molecular reaction network Non-genotoxic stress 1507 p38/JNK1 2915 modeling 1065 Normal breast tissue 2723 p53-dependent 3269 Morphogenesis 9 Notch1 517 p53 functional assay 2249 Motility 3227 Nov 747 p53-independent 3269 Mouse skin model 1267 NPC 1869 p53 missense mutation 2103 Mouse 1723 Nuclear 1429 P53 protein 3013 MSH2 1803 Nuclear body 2041 p53 stabilization 2827 mSin3 2549 Nuclear exclusion 3423 p53 105, 283, 321, 349, 453, 685, MTG8 protein 2609 Nuclear export 3309 883, 957, 1041, 1113, 1171, 1183, Multimer 2185 Nuclear hormone receptors 563 1187, 1299, 1351, 1369, 1391, Multivariate prognostic analysis Nuclear retention 2151 1507, 1593, 1603, 1617, 1713, 1183 Nucleophosmin/B23 915 1759, 1789, 2115, 2177, 2205, MuLV 517 Nucleosome 1171 2213, 2395, 2413, 2527, 2695, Murine lymphomas 803 Nucleus 1851 2747, 2965, 2989, 3105, 3123, Muscle b-HLH proteins 3369 Nude mice 3323 3317, 3461 Mutant epidermal growth factor p53, 1241, 2469 receptor 1197 p537/7 mouse ®broblasts 721 Mutant p53 997, 1429, 3169 ODC 387 p85b 1767 Mutation 69, 497, 541, 677, 1091, Oligodendrocyte-Myelin p96 1561 1241, 2345, 2469, 2767, 3397, glycoprotein 1525 p185 547 3435 Oligodendrocytes 2123 p185neu 2835 Mutation types 1671 Oligodendroglioma 2259 p185neu 1197 Mutational analysis 3105 Oligomerization 2413 P190 Bcr/Abl 2029 Mutations 789, 2115, 3177 OMgp 1525 p204 1543 Mutator phenotype 1125 Oncogene 665, 1021, 1249, 1325, p300 2695, 3069 myc 211, 2629 1625, 1973, 2087, 2407, 2819, PAb1620 1993 Myc 967 2965, 3159, 3345, 3435 Paired-like homeodomain 227 Myc/Mad/leucine 1149 Oncogenes 737, 1921, 3403 Pancreas cancer 625 Myeloid cell proliferation 1749 Oncogenesis 1633 Pancreatic cancer 1593 MyoD 273 Oncogenic transformation 809, Papilloma 2205 Myogenesis 273, 3369 1277 PARP 3461 Oral and laryngeal 2983 Patched 1091 Oral cancer 1921, 3379 Pbx 3403 N-myc 1131 Ornithine decarboxylase antizyme PC12 443 N-myc 3337 3379 PCNA 311, 369, 431 N33 3197 Ovarian cancer 1, 1561, 3455 PCR diagnosis 321 Neoplasia 681 Ovarian tumours 3013 PCR-SSCP 951 Neoplastic transformation 3387 Ovary 197, 555, 2381 PDGF a-receptor 1229 Nerve growth factor 3253 Over-representation 2617 PDGF 505, 3349 Nervous system 1813 Overexpression 2997, 3227 PDGF receptor 2425 Nested PCR 1863 Oxidative DNA damage 3083 PDGF signaling 1525 Neural 471 PDGFb receptor 2321 Neural cells 2609 PDZY 643 Neural tissue 77 p-glycoprotein 2087 PEA3 301 Neuralized 1009 p15INK4b 803 Peptide 1903 Neuregulin 9 p16 1, 265 Peptide delivery 587 Neuroblastoma 293, 3337 p16INK4A 497 Peritoneal dissemination 2681 Neuroendocrine di€erentiation p16INK4a 587, 1113, 3087 Peritoneal neoplasia 3455 1593 p16INK4a 2723 Permeability transition 1055, 2265 Neuro®bromin 1525 p16INK4a-a 803 PGX-3 227 Neuron 1571 p16INK4a-b 803 Ph translocation 2029 Neuronal di€erentiation 2197 p19Ink4D 2075 Philadelphia chromosome 1533 Neuronal signaling pathways 2657 p21 431, 705, 957, 1113, 1513 Phorbol ester 131 Keyword Index ± Volume 16

3536 Phosphatases 533 Protein isoforms 77 Retinoid receptors 3471 Phosphatidylinositol 3-kinase 1767, Protein kinase 1813, 2965, 3029 Retinoids 3337 2407 Protein kinase B/Akt 903 Retroviral insertion mutagenesis

Phosphatidylinositol 4,5P2 2303 Protein kinase C 1649, 1939 1399 Phosphatidylinositol-3 kinase 2975 Protein kinase Cd 1643 Retroviral vector 1487, 3285 Phospholipase C 1691 Protein kinase p34cdc2 105 Retrovirus 517, 3115 Phosphorothiate ODN 1899 Protein stability 1289 Retroviruses 3177 Phosphorylation 1031, 1325 Protein-protein interaction 2283, Rev 1851 Phosphorylation, binding sites 505 3369 Reverse transcriptase 1723 Phosphotyrosine 43 Protein-tyrosine kinase 2927 Reverse transcription 1863 Physical map 1639 Proto-oncogene 1681 RFX1 1779 PI 3-kinase 903, 1981 Pseudogene 2403 Rho 2011, 3279 Pituitary cells 1981 PTB domain 891 Rho GDI 3279 Pituitary tumour 69 PTEN 1743, 2879 Rho GEF 2513 PKC 763, 1665 PTEN mutations 2259 Rho GEP 3279 PKC-d 53, 3357 PTEN/MMAC1 89, 3331, 3397 Rho GTPase 2513 PKC-e 53 PTEN/MMAC1 3215 Ribonucleoproteins 979 PKCe 3345 PTH2 89 RING ®nger 1097 Placental type alkaline phosphatase Pyrimidine dimers 2827 RING ®nger protein 2541 2935 RING3 nuclear kinase 1223 PLAG1 1409 Ring 2905 Plasminogen 3097 Quantitative PCR 3203 RMA polymerase II 3461 Platelet 2773 Quercetin 2739 RNA ®ngerprinting 2935 Platelet-derived growth factor 1571 RNA stability 3413 Pleckstrin homology domain 2303 RNAse L 3323 Pleckstrin homology (PH) domain Radiation resistance 523 Ron 27 2597 Radicicol 2639 RON 2927 Pleomorphic adenoma of the Radioresistance 1789 RT ± PCR 167, 671, 2815 salivary glands 865 Raf 613, 1899, 2565, 2639, 2781 RxRE 3309 Pleomorphic adenoma 1409 raf 211 RXR 273 PLGF 359 Raf-1 1417, 3345 PLZF 1945, 2549 RAR 273 PLZF/RARa 1945 Ras 613, 1417, 1467, 1981, 2303, Saccharomyces cerevisiae 2527 PML 1945, 2843, 2905 2597, 2781, 3057 Salivary gland carcinomas 83 PML/RARa 1945 ras 2205 SAPKs 661 Pocket protein 1373 ras 1267 SB203580 575 Point mutations 755 ras cooperation 2165 Schizosaccharomyces pombe 1759 Polycomb group proteins 2541 ras oncogene 575, 2357 SCLC 89 Polyomavirus 903, 2975 Rat model 713 Secretion pattern 2503 Polyomavirus LT 1963 RB 1 SENCAR mouse 3203 Post-transcriptional modi®cation Rb 1267, 1289, 1931, 2489 Sequence variation 1869 459 Rb1 481 Sequence 1993, 3189 pRB 227 Rearrangement 677 Sequestration 2041 pRb 481 Receptor 471, 505, 1209 Serine-threonine kinase 2407 Pre-B leukemia/lymphoma 2029 Receptor density 179 SH2 domain 891 Prenylation and antitumor ecacy Receptor tyrosine kinase 1681, SH3 1903 1467 1691, 2657, 3047, 3177 SH3 domain 1561 Prognostic factor 2469 Reciprocal transcript 671 Shb 891 Prognostic markers 2447 Reconstitution 2781 Shc 1691 Programmed cell death 1055, 1899, Redox regulation 2935 Sheep 2165 2123, 2265 Redox signaling 2935 SHP-2 3019 Prolactin 1981 Regulation 655, 763 SHPS-1 3019 Proliferation 359, 381, 443, 1691, Regulation of gene expression 1633 Signal transduction 211, 737, 825, 2151, 2213, 2935, 3379, 3403 Renal cell cancer 3215 1249, 1493, 1507, 1633, 2513, Promoter 817 Renal cell carcinoma 713 2671, 3029, 3047 Prostate cancer 481, 1863, 2879, Representational di€erence analysis Signal transduction pathway 575 3069, 3143 1921 Signaling 417, 113, 1731 Prostate cancer cell lines 1913 Resistance 2345 Silencing 113 Prostate cancer cells 1487 Ret 293 Single stage PCR 1863 Prostate carcinoma 1743 RET 597 Single-strand conformation Protease 2177 RET 991, 2295 polymorphism 789 Proteases 2265 RET oncogene 671 Sis 613 Proteasome 1131, 1333 Retinoblastoma 2729, 3211 SkBr3 cell line 3285 Proteasomes 2051 1065 Ski oncogene 1579 Protein expression 497 Retinoic acid 273, 915, 3471 Skin cancer 853 Protein interaction 3261 Retinoic acid receptors 3369 Skin cancer and MAPK 1501 Keyword Index ± Volume 16

3537 SLF 179 Thrombin 2773 TSG101 2815 Small cell lung cancer 153 Thymic lymphoma 2747 TSG101/CC2 677 Soft tissue sarcoma 1183 Thyroglobulin 167 TSH receptor 985 Somatic mutation 3151 Thyroid 1455, 2435 TSV40 1041 Son-of-sevenless (Sos) 2597 Thyroid cancer 665 Tuberin 2197 Sonic hedgehog 1611 Thyroid cells 2357 Tuberous sclerosis 2197 SOS 2303 TIMP-1 2419 Tumor cell lines 635 Sp1 1931 Tissue-type plasminogen activator Tumor cells 1309 SpcDNA 2311 625 Tumor growth 1309 Spermatogenesis 1773 TNFa 575 Tumor progression 2447 Spi-1/PU.1 1357, 2989 Tob/BTG1 family 2687 Tumor progression immunotherapy Splicing 3291 Toxin 1209 2503 Squamous carcinoma 2983 TP53 1671, 2345 Tumor promotion 3387 Squamous cell carcinoma 2205 TP53 21, 3291 Tumor suppressor 77, 89, 541, 681, SRC 3019 TPA 1665, 2489 1141, 1655, 2283, 2381, 2395, Src 1649, 2185, 3357 TRAF 1869 2479, 2797, 3087 Src kinases 1749 Transactivation 883, 1299, 2001, Tumor suppressor gene 257, 1009, SSCP 2469, 3211 2367, 2413, 2527 1863, 2159, 2739 Stat 505 Transactivator 1879 Tumor suppressor gene (TSG) 909 STAT1 2647 Transcription 283, 685, 1171, 1369, Tumor suppressors 399 STAT5 3047 1373, 1513, 1713, 1779, 2177, Tumor-derived mutants 2527 STATs 1749 2489, 2695, 2843 Tumorigenicity 53, 1839, 1913 Staurosporine 459 1021, 1357, Tumorigenesis 301 Stem cell 945 2065, 2479, 2711 Tumour suppressor gene 2213, Stem cells 381, 3003 Transcription factors 399, 2739 3083 Stk 27 Transcription regulation 3261 Tumour suppressor 587, 789 Stress 2915 Transcription-coupled repair 2827 Two-hybrid 643 Structure-function 1993 Transcriptional activation 1187, Two-hybrid system 2657 Subpopulation analysis 1259 1625 Tyrosinase 1665 Subtractive cloning 327 Transcriptional activation domain Tyrosine kinase 1249, 1383, 2435, Subtractive hybridization 2945, 3169 2585, 2835, 2855 3379 Transcriptional regulation 459, Tyrosine phosphorylation 237, Survival signals 825 2739 797, 843, 2321, 3019 SV40 665 Transcriptional repression 967, Tyrosine phosphorylation of SV40 large T antigen 547 2287, 2629, 2957 Bcr 141 SV40 T-antigen 2103 Transdi€erentiation 3057 Transfection 1701 Transformation 43, 53, 179, 737, U.V. 523 T cell receptor 891 1383, 1429, 1973, 2435, 2585, U937 925 t(12;21) translocation 2895 2711, 2835, 3133 Ubiquitin 1131 T-prolymphocytic leukaemia 789 Transformation suppression 2639 Ubiquitin hydrolase, 1097

TAFIIs 1633 Transformations 3177 Ubiquitin protease 153 Tamoxifen 409 Transforming growth factor-b Ultraviolet irradiation 2827 Target gene 2945 951 Ultraviolets A and B 661 Targeted mutagenesis 517 Transgenic 1963, 2989 Urokinase receptor 625 TATA-less promoter 2395 Transgenic animals 2103 Urokinase-type plasminogen Tax 643 Transgenic medaka 1681 activator 625 Taxol 2087 Transgenic mice 203, 517, 2333, Ursolic acid 771 TCF/SRF 661 2419, 2965 USF 2629 Tec 2773 Transgenic mouse model 997 USF2 763 TEL/ETV6 proteins 2895 Translation 423 UV-B 1501 Telemere 1723 Translational 763 UV-C 1501 Telomerase 381, 979, 1217, 1345 Translocation 945, 1351 UVB 2205 1723, 2243, 3323 Transmembrane four superfamily Telomere 1825 3143 Temperature sensitive mutant p53 Transport 1851 V(D)J recombination 1553 1593, 3423 trans-receptor inhibition 1197 v-Src 2017, 3349 TEP1 2403 Transversions 1125 VEGF 349, 2585 Teratocarcinoma 95, 3471 Trio 147 Ventricular zone 2687 terc 1345 TRK oncogenes 809 Vimentin 3423 Testicular germ cell tumors 2617 TrK 825 Viral transformation 563 Tetracycline 369, 431, 1879 Truncated growth factor Vitamin D 2729 TGFb-RII 2767 receptors 3243 TGFb 95 Truncation 1571 TGF-b1 1455, 3349, 3445 TRX 3233 WAF1 1507 Therapy-induced p53 mutation 249 TSC2 2197 waf1/cip1 3115 Keyword Index ± Volume 16

3538 Wilms' tumor 2033, 2041, 2815 Xiphophorus 1681 YAC clones 1639 Wnt 2819 Xmrk 1681 Yeast 121, 1625, 2115 WT1 925, 1973, 2033, 2041 XPA 2205 Yeast two-hybrid system 873 X-ray 705

X protein 2051 Zipper/helix ± loop ± helix 1149 Xenopus 883 Y882 2835